Sullivan L J, McCurrach F, Lee S, Taylor H R, Rolando M, Marechal-Courtois C, Creuzot-Garcher C, Easty D L, Karabatsas C, Bingh Hoh M, Faschinger C, Laroche L
Corneal Clinic, Royal Victorian Eye and Ear Hospital, East Melbourne, Australia.
Ophthalmology. 1997 Sep;104(9):1402-8. doi: 10.1016/s0161-6420(97)30124-9.
Carbomer gel is a water-soluble polymeric resin that has been reported to maintain the tear film in contact with the eye for an extended period. The efficacy and safety of this new artificial tear were assessed.
A multicenter, single-masked, randomized, placebo-controlled study was carried out on 123 patients with moderate-to-severe dry eyes. The placebo was a mannitol solution with benzalkonium chloride 0.008% as preservative. Patients were observed over an 8-week period, and subjective and objective changes analyzed, compared to a baseline of no therapy, after 1 to 7 days washout period from previous medication.
All primary subjective symptoms decreased significantly in the carbomer gel-treated group compared to the placebo group (i.e., dryness, discomfort, and foreign body sensation). The carbomer gel also significantly improved the rose bengal staining score relative to placebo. When data for the primary subjective efficacy variables were stratified for disease severity, there was a statistically significant improvement from baseline by day 10 for severely affected patients and from day 42 for patients with moderate disease. Secondary subjective symptoms that improved significantly in the tear gel group compared to placebo were photophobia, erythema, tear breakup time, blurry-filmy, dry-sandy sensation, and physician impression. However, no significant improvements in the secondary subjective symptoms of tearing, itching, scaling, conjuctival discharge, palpebral conjunctival redness, bulbar conjuctival redness, conjunctival luster, relief of discomfort, ease of use, and overall acceptability were found in either group over the baseline score. In addition, neither carbomer gel nor placebo improved the baseline fluorescein staining score or the Schirmer test score. Two patients suffered local allergic reactions to the carbomer gel or its preservative, which settled on withdrawal of the medication.
Carbomer gel was more efficacious than was placebo in improving a number of subjective and objective symptoms of moderate-to-severe dry eye syndrome. The results of this study indicate that carbomer gel was a safe as was the placebo.
卡波姆凝胶是一种水溶性聚合树脂,据报道它能使泪膜与眼睛长时间接触。对这种新型人工泪液的疗效和安全性进行了评估。
对123例中重度干眼症患者进行了一项多中心、单盲、随机、安慰剂对照研究。安慰剂是含有0.008%苯扎氯铵作为防腐剂的甘露醇溶液。在停药1至7天的洗脱期后,与未治疗的基线相比,对患者进行了为期8周的观察,并分析了主观和客观变化。
与安慰剂组相比,卡波姆凝胶治疗组的所有主要主观症状均显著减轻(即干涩、不适和异物感)。与安慰剂相比,卡波姆凝胶还显著改善了孟加拉玫瑰红染色评分。当对主要主观疗效变量的数据按疾病严重程度进行分层时,重度受累患者在第10天、中度疾病患者在第42天相对于基线有统计学显著改善。与安慰剂相比,泪凝胶组显著改善的次要主观症状有畏光、红斑、泪膜破裂时间、模糊-薄膜感、干沙感和医生印象。然而,两组在流泪、瘙痒、脱屑、结膜分泌物、睑结膜充血、球结膜充血、结膜光泽、不适缓解、易用性和总体可接受性等次要主观症状方面,与基线评分相比均无显著改善情况。此外,卡波姆凝胶和安慰剂均未改善基线荧光素染色评分或泪液分泌试验评分。两名患者对卡波姆凝胶或其防腐剂出现局部过敏反应,停药后症状缓解。
在改善中重度干眼综合征的一些主观和客观症状方面,卡波姆凝胶比安慰剂更有效。本研究结果表明,卡波姆凝胶与安慰剂一样安全。